整理 | GLP1减重宝典内容团队12月20日,美国食品药品管理局最终决定结束礼来公司 (LLY) 重磅 GLP-1 产品替尔泊肽的药品短缺问题。礼来公司股价在周五收盘前盘前交易中上涨 9%。此前,复合药房提起的诉讼迫使 FDA 宣布审查其 10 月份的原始决定。复合药房投资数百万美元批量购买关键成分来制造山寨药品,现在他们已收到通知,停止其山寨行为。▍GLP-1短缺造成的山寨现状这一新闻引发了...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.